J&J Commits To Supply Chain Reforms In Benzene Class Action Settlement

Already in receipt of more than $9m in refund requests from purchasers of potentially benzene-contaminated Neutrogena and Aveeno sunscreen products following a July 2021 recall, J&J now is finalizing a US multidistrict class action settlement that will add to those costs and require steps to prevent further benzene issues.

Johnson & Johnson will compensate consumers US-wide for purchases of potentially benzene-tainted Neutrogena and Aveeno aerosol sunscreen products – and a few non-aerosol sunscreens as well – as part of a multidistrict class action settlement preliminarily approved in Florida federal court on 28 March.

The New Brunswick, NJ firm also will undertake measures in supply chain remediation to ensure against future benzene risks to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.